Pegvisomant therapy for acromegaly

References

• Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin. Endocrinol. (Oxf.)12, 71–79 (1980).
   PubMed Web of Science ®Google Scholar
• Melmed S. Acromegaly. In: The Pituitary. Blackwell Science, Cambridge, MA 413–442 (1995).
   Google Scholar
• Nabarro JD. Acromegaly. Clin. Endocrinol. (Oxf.)26, 481–512 (1987).
   PubMed Web of Science ®Google Scholar
• Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore)73, 233–240 (1994).
   PubMed Web of Science ®Google Scholar
• Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J. Neurosurg.89, 353–358 (1998).
   PubMed Web of Science ®Google Scholar
• Swearingen B, Barker FG 2nd, Katznelson L et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab.83, 3419–3426 (1998).
   PubMed Web of Science ®Google Scholar
• Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin. Endocrinol. (Oxf.)58, 86–91 (2003).
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab.89, 667–674 (2004).
   PubMed Web of Science ®Google Scholar
• Spagnoli A, Rosenfeld RG. The mechanisms by which growth hormone brings about growth. The relative contributions of growth hormone and insulin-like growth factors. Endocrinol. Metab. Clin. N. Am.25, 615–631 (1996).
   PubMedGoogle Scholar
• Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm. IGF Res.13, 171–184 (2003).
   PubMed Web of Science ®Google Scholar
• Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly – the experience of a dedicated pituitary surgeon. QJM92, 741–745 (1999).
   PubMed Web of Science ®Google Scholar
• Shimon I, Cohen ZR, Ram Z, Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery48, 1239–1243 (2001).
   PubMedGoogle Scholar
• Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol. Metab. Clin. N. Am.21, 693–712 (1992).
   PubMed Web of Science ®Google Scholar
• Barkan AL, Halasz I, Dornfeld KJ et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J. Clin. Endocrinol. Metab.82, 3187–3191 (1997).
   PubMed Web of Science ®Google Scholar
• Epaminonda P, Porretti S, Cappiello V, Beck-Peccoz P, Faglia G, Arosio M. Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin. Endocrinol. (Oxf.)55, 183–189 (2001).
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J. Clin. Endocrinol. Metab.85, 2476–2482 (2000).
   PubMed Web of Science ®Google Scholar
• Barrande G, Pittino-Lungo M, Coste J et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J. Clin. Endocrinol. Metab.85, 3779–3785 (2000).
   PubMed Web of Science ®Google Scholar
• Powell JS, Wardlaw SL, Post KD, Freda PU Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J. Clin. Endocrinol. Metab.85, 2068–2071 (2000).
   PubMed Web of Science ®Google Scholar
• Vance ML. Gamma knife radiotherapy for pituitary adenomas. Presented at: 84th Annual Meeting of the Endocrine Society, June 19–22, San Francisco, CA, USA (2002).
   Google Scholar
• Brada M, Ford D, Ashley S et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. Br. Med. J.304, 1343–1346 (1992).
   PubMed Web of Science ®Google Scholar
• Wass JA. Long-term effects of radiotherapy for acromegaly. Metabolism45, 107–108 (1996).
   PubMedGoogle Scholar
• Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol. Metab. Clin. N. Am.21, 713–735 (1992).
   PubMed Web of Science ®Google Scholar
• Abs R, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab.83, 374–378 (1998).
   PubMed Web of Science ®Google Scholar
• Freda PU. How effective are current therapies for acromegaly? Growth Horm. IGF Res.13(Suppl. A), S144–S151 (2003).
   Google Scholar
• Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD. Cabergoline therapy of growth hormone and growth hormone/prolactin secreting pituitary tumors. Pituitary7, 21–30 (2004).
   PubMedGoogle Scholar
• Caron P, Beckers A, Cullen DR et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J. Clin. Endocrinol. Metab.87, 99–104 (2002).
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab.90, 4465–4473 (2005).
   PubMed Web of Science ®Google Scholar
• Freda PU. Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab.87, 3013–3018 (2002).
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Chihara K, Freda PU et al. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin. Endocrinol. Metab.88, 4759–4767 (2003).
   PubMed Web of Science ®Google Scholar
• Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science256, 1677–1680 (1992).
   PubMed Web of Science ®Google Scholar
• de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science255, 306–312 (1992).
   PubMed Web of Science ®Google Scholar
• Abdel-Meguid SS, Shieh HS, Smith WW, Dayringer HE, Violand BN, Bentle LA. Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc. Natl Acad. Sci. USA84, 6434–6437 (1987).
   PubMed Web of Science ®Google Scholar
• Chen WY, Chen N, Yun J, Wagner TE, Kopchick JJ. In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs. J. Biol. Chem.269, 20806 (1994).
   PubMedGoogle Scholar
• Muller AF, Kopchick JJ, Flyvbjerg A, van der Lely AJ. Clinical review 166: growth hormone receptor antagonists. J Clin. Endocrinol. Metab.89, 1503–1511 (2004).
   PubMed Web of Science ®Google Scholar
• Goffin V, Touraine P. Pegvisomant Pfizer/Sensus. Curr. Opin. Investig. Drugs5, 463–468 (2004).
   PubMedGoogle Scholar
• Somavert® Pegvisomant for Injection. Package Insert. Pfizer Inc., NY, USA December (2005).
   Google Scholar
• Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science256, 1677–1680 (1992).
   PubMed Web of Science ®Google Scholar
• Kopchick JJ. Discovery and mechanism of action of pegvisomant. Eur. J. Endocrinol.148(Suppl. 2), S21–S25 (2003).
   Google Scholar
• Wells JA, Cunningham BC, Fuh G et al. The molecular basis for growth hormone-receptor interactions. Recent Prog. Horm. Res.48, 253–275 (1993).
   PubMedGoogle Scholar
• Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev.23, 623–646 (2002).
   PubMed Web of Science ®Google Scholar
• Ross RJ, Leung KC, Maamra M et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J. Clin. Endocrinol. Metab.86, 1716–1723 (2001).
   PubMed Web of Science ®Google Scholar
• Clark R, Olson K, Fuh G et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem.271, 21969–21977 (1996).
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med.342, 1171–1177 (2000).
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet358, 1754–1759 (2001).
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Bennett WF, Zib KA. Single-dose safety and pharmacokinetics of B2036-PEG (Somavert) after subcutaneous administration in healthy volunteers. J. Clin. Pharmacol.37, 869 (1997).
   Web of Science ®Google Scholar
• Rodvold KA, van der Lely AJ. Pharmacokinetics and pharmacodynamics of B2036-PEG, a novel growth hormone receptor antagonist, in acromegalic subjects. Proceedings of the 81st Annual Endocrine Society Meeting, San Diego CA, USA, June 12–15 (1999).
   Google Scholar
• Thorner MO, Strasburger CJ, Wu Z et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J. Clin. Endocrinol. Metab.84, 2098–2103 (1999).
   PubMed Web of Science ®Google Scholar
• van der Lely AJ , Lamberts SWJ , Barkan A et al. A six week, double blind, placebo controlled study of a growth hormone antagonist, B2036-PEG, in acromegalic patients. Proceedings of the 80th Annual Meeting of the Endocrine Society. New Orleans, LA, USA.
   Google Scholar
• Herman-Bonert VS, Zib K, Scarlett JA, Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J. Clin. Endocrinol. Metab.85, 2958–2961 (2000).
   PubMed Web of Science ®Google Scholar
• Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM, Trainer PJ. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur. J. Endocrinol.145, 451–456 (2001).
   PubMed Web of Science ®Google Scholar
• Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm. IGF Res.12, 418–424 (2002).
   PubMed Web of Science ®Google Scholar
• Drake WM, Rowles SV, Roberts ME et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur. J. Endocrinol.149, 521–527 (2003).
   PubMed Web of Science ®Google Scholar
• Barkan AL, Burman P, Clemmons DR et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J. Clin. Endocrinol. Metab.90, 5684–5691 (2005).
   PubMed Web of Science ®Google Scholar
• Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin. Endocrinol. (Oxf.)36, 271–279 (1992).
   PubMed Web of Science ®Google Scholar
• Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201–995 in 58 acromegalic patients. French SMS 201–995 approximately equal to Acromegaly Study Group. J. Clin. Endocrinol. Metab.71, 391–397 (1990).
   Google Scholar
• Breidert M, Pinzer T, Wildbrett J, Bornstein SR, Hanefeld M. Long-term effect of octreotide in acromegaly on insulin resistance. Horm. Metab. Res.27, 226–230 (1995).
   PubMed Web of Science ®Google Scholar
• Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin. Endocrinol. (Oxf.)56, 303–311 (2002).
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Fairfield WP, Katznelson L et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J. Clin. Endocrinol. Metab.87, 1692–1699 (2002).
   PubMed Web of Science ®Google Scholar
• Fairfield WP, Sesmilo G, Katznelson L et al. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin. Endocrinol. (Oxf.)57, 385–390 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J. Clin. Endocrinol. Metab.88, 5650–5655 (2003).
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM, Monson JP. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J. Clin. Endocrinol. Metab.86, 2989–2992 (2001).
   PubMed Web of Science ®Google Scholar
• Jorgensen JO, Feldt-Rasmussen U, Frystyk J et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab.90, 5627–5631 (2005).
   PubMed Web of Science ®Google Scholar
• Feenstra J, de Herder WW, ten Have SM et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet365, 1644–1646 (2005).
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Muller A, Janssen JA et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J. Clin. Endocrinol. Metab.86, 478–481 (2001).
   PubMed Web of Science ®Google Scholar
• Jehle S, Reyes CM, Sundeen RE, Freda PU. COMMENT: Alternate day administration of pegvisomant maintains normal serum insulin like growth factor-I (IGF-I) levels in patients with acromegaly. J. Clin. Endocrinol. Metab. (2004).
   PubMedGoogle Scholar
• Parkinson C, Burman P, Messig M, Trainer PJ. The influence of gender and weight on the dose of pegvisomant required to normalize serum IGF-1 in patients with active acromegaly. Proceedings of the 85th Annual Endocrine Society Meeting; New Orleans, LA, USA, June 16–19 (2004).
   Google Scholar
• Drake WM, Trainer PJ. Clinical use of pegvisomant for the treatment of acromegaly. Treat. Endocrinol.2, 369–374 (2003).
   PubMedGoogle Scholar
• Biering H, Saller B, Bauditz J et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur. J. Endocrinol.154, 213–220 (2006).
   PubMed Web of Science ®Google Scholar
• Ho KK. Place of pegvisomant in acromegaly. Lancet358, 1743–1744 (2001).
   PubMedGoogle Scholar
• Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur. J. Endocrinol.153, 187–193 (2005).
   PubMed Web of Science ®Google Scholar